GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (FRA:K6S) » Definitions » EV-to-EBITDA

Mira Pharmaceuticals (FRA:K6S) EV-to-EBITDA : -0.79 (As of Jun. 25, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Mira Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mira Pharmaceuticals's enterprise value is €6.52 Mil. Mira Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-8.29 Mil. Therefore, Mira Pharmaceuticals's EV-to-EBITDA for today is -0.79.

The historical rank and industry rank for Mira Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

FRA:K6S' s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.52   Med: 0   Max: 0
Current: -0.78

FRA:K6S's EV-to-EBITDA is ranked worse than
100% of 710 companies
in the Drug Manufacturers industry
Industry Median: 13.815 vs FRA:K6S: -0.78

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-25), Mira Pharmaceuticals's stock price is €0.655. Mira Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.792. Therefore, Mira Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Mira Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Mira Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals EV-to-EBITDA Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBITDA
- - -1.28

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -9.24 -1.28 -1.42

Competitive Comparison of Mira Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mira Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mira Pharmaceuticals's EV-to-EBITDA falls into.



Mira Pharmaceuticals EV-to-EBITDA Calculation

Mira Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6.520/-8.285
=-0.79

Mira Pharmaceuticals's current Enterprise Value is €6.52 Mil.
Mira Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mira Pharmaceuticals  (FRA:K6S) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Mira Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.655/-0.792
=At Loss

Mira Pharmaceuticals's share price for today is €0.655.
Mira Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.792.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Mira Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mira Pharmaceuticals (FRA:K6S) Business Description

Comparable Companies
Traded in Other Exchanges
Address
855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205
Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.

Mira Pharmaceuticals (FRA:K6S) Headlines

No Headlines